DNLI News and Press, Denali Therapeutics Inc. From 05/07/20

SOUTH SAN FRANCISCO, May 07, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier ("BBB") for neurodegenerative diseases, today reported financial results ...

Molina Healthcare (NYSE: MOH ) is providing virtual urgent care to Marketplace members vis its partnership with Teladoc (NYSE: TDOC ) and is expanding Teladoc to all Medicare and Medicaid members. It is covering COVID-19 screening tests and office visits, urgent care or ER visits associati...

SOUTH SAN FRANCISCO, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (“BBB”) for neurodegenerative diseases, today p...

IDEAYA Biosciences (NASDAQ: IDYA ) initiated with Buy rating and $12 (192% upside) price target at Roth Capital. More news on: IDEAYA Biosciences, Inc., Menlo Therapeutics Inc., Amarin Corporation plc, Healthcare stocks news, Stocks on the move, , Read more ...

Denali Therapeutics (NASDAQ: DNLI ): Q4 GAAP EPS of -$0.56 beats by $0.05 . More news on: Denali Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Alector (NASDAQ: ALEC ) initiated with Buy rating and $44 (52% upside) price target at Stifel. More news on: Alector, Inc., Aridis Pharmaceuticals, Inc., BioLife Solutions, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the closing of its upsized underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $23.00 per share, which includes the exercise in...

Denali Therapeutics (NASDAQ: DNLI ) has priced its public offering of 7,826,087 common shares at $23/share, for expected gross proceeds of $180M. More news on: Denali Therapeutics Inc., Healthcare stocks news, Read more ...

SOUTH SAN FRANCISCO, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 7,826,087 shares of its common stock at a price to the public of $23.00 per share. All of the shares are to be sold by De...

Denali Therapeutics (NASDAQ: DNLI ) intends to offer $150M shares of its common stock in a public offering. More news on: Denali Therapeutics Inc., Healthcare stocks news, , Read more ...